Wednesday, December 16, 2015
When a site is chosen for a clinical trial, it can be gratifying and frustrating at the same time.
After a five- to eight-year decline, investigator-initiated trials (IITs) are gaining renewed interest as more biopharmaceutical companies are using them as a creative and cost-effective way to innovate and further improve patient safety.
hVIVO, a U.K.-based provider of human disease models, and Everbridge, a global provider of SaaS-based unified critical communications solutions, are joining forces to offer a next-generation, virtual clinical trial platform that has the potential to transform the trial volunteer experience.
Qlik, a Radnor, Pa.-based visual analytics provider, is integrating its mobile visual analytical applications with Veeva CRM Mobile for self-service data discovery and user-driven guided analytics as the newest initiative in its partnership with Veeva Systems, a cloud-based software provider for the global life sciences industry.
Parexel International, a global biopharmaceutical services provider, has introduced IMPACT Express Clinical Trial Management System (CTMS). IMPACT Express provides a quick-to-implement, cost-effective clinical trial management solution to simplify clinical trial management and monitoring for small to mid-sized biopharmaceutical companies.
GHO Capital, a European specialist healthcare investor, has acquired Quotient Clinical, a Nottingham, U.K.-based provider of outsourced, early-stage drug development services to the pharmaceutical industry. Employing more than 280 professionals, Quotient Clinical enables pharmaceutical and biotechnology customers to improve R&D productivity and accelerate drug development timelines.
Never before have operating conditions for clinical studies been more difficult. Clinical operations groups face growing pressure to get drugs to market faster while improving efficiencies and study quality. Development costs continue to rise. At the same time, the logistics of conducting a clinical trial have become more complex in the increasingly competitive and regulated environment.
The Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke University, has unveiled a new model for the informed consent process designed to improve the ability of patients to make educated decisions about clinical research participation.